Aim Immunotech Stock Analysis
| AIM Stock | USD 0.23 0.02 9.52% |
AIM ImmunoTech is undervalued with Real Value of 1.12 and Target Price of 3.83. The main objective of AIM ImmunoTech stock analysis is to determine its intrinsic value, which is an estimate of what AIM ImmunoTech is worth, separate from its market price. There are two main types of AIM ImmunoTech's stock analysis: fundamental analysis and technical analysis.
The AIM ImmunoTech stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. AIM ImmunoTech is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. AIM Stock trading window is adjusted to America/New York timezone.
AIM |
AIM Stock Analysis Notes
About 14.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.47. AIM ImmunoTech last dividend was issued on the 11th of June 2019. The entity had 1:44 split on the 11th of June 2019. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Aim Immunotech operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 21 people. For more info on AIM ImmunoTech please contact Esq JD at 352 448 7797 or go to https://aimimmuno.com.AIM ImmunoTech Investment Alerts
| AIM ImmunoTech generated a negative expected return over the last 90 days | |
| AIM ImmunoTech has high historical volatility and very poor performance | |
| AIM ImmunoTech has some characteristics of a very speculative penny stock | |
| AIM ImmunoTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 202 K. Reported Net Loss for the year was (28.96 M) with loss before taxes, overhead, and interest of (715 K). | |
| AIM ImmunoTech has about 27.05 M in cash with (21.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| AIM ImmunoTech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Bullish Ai-Media Technologies Insiders Loaded Up On AU3.17m Of Stock |
AIM ImmunoTech Upcoming and Recent Events
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
AIM Largest EPS Surprises
Earnings surprises can significantly impact AIM ImmunoTech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-13 | 2022-04-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2022-05-13 | 2022-03-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2021-11-15 | 2021-10-31 | -0.07 | -0.08 | -0.01 | 14 |
AIM Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 14.66 M.AIM Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.70) | (1.61) | |
| Return On Capital Employed | (2.97) | (2.83) | |
| Return On Assets | (1.49) | (1.42) | |
| Return On Equity | (2.83) | (2.69) |
Management Efficiency
AIM ImmunoTech has Return on Asset of (0.8004) % which means that on every $100 spent on assets, it lost $0.8004. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5479) %, meaning that it generated no profit with money invested by stockholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to grow to -1.61. In addition to that, Return On Capital Employed is likely to grow to -2.83. At this time, AIM ImmunoTech's Total Assets are very stable compared to the past year. As of the 2nd of December 2024, Non Current Assets Total is likely to grow to about 8.5 M, while Intangible Assets are likely to drop about 1.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.21 | 0.20 | |
| Tangible Book Value Per Share | 0.16 | 0.15 | |
| Enterprise Value Over EBITDA | (0.53) | (0.55) | |
| Price Book Value Ratio | 2.09 | 1.98 | |
| Enterprise Value Multiple | (0.53) | (0.55) | |
| Price Fair Value | 2.09 | 1.98 | |
| Enterprise Value | 16.7 M | 15.8 M |
The operational strategies employed by AIM ImmunoTech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Operating Margin (73.88) | Beta (0.36) | Return On Assets (0.80) | Return On Equity (1.55) |
Technical Drivers
As of the 2nd of December, AIM ImmunoTech shows the Risk Adjusted Performance of (0.07), mean deviation of 3.61, and Coefficient Of Variation of (957.15). AIM ImmunoTech technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm AIM ImmunoTech standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if AIM ImmunoTech is priced adequately, providing market reflects its regular price of 0.23 per share. As AIM ImmunoTech appears to be a penny stock we also recommend to validate its jensen alpha numbers.AIM ImmunoTech Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. AIM ImmunoTech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for AIM ImmunoTech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
AIM ImmunoTech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AIM ImmunoTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on AIM ImmunoTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AIM ImmunoTech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AIM ImmunoTech Outstanding Bonds
AIM ImmunoTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AIM ImmunoTech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AIM bonds can be classified according to their maturity, which is the date when AIM ImmunoTech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| ACACN 36 15 MAR 27 Corp BondUS009090AA91 | View | |
| ACACN 525 01 APR 29 Corp BondUS00909DAA19 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| ACACN 4125 15 MAY 25 Corp BondUS009089AA11 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
AIM ImmunoTech Predictive Daily Indicators
AIM ImmunoTech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AIM ImmunoTech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
AIM ImmunoTech Forecast Models
AIM ImmunoTech's time-series forecasting models are one of many AIM ImmunoTech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AIM ImmunoTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About AIM Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how AIM ImmunoTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AIM shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as AIM ImmunoTech. By using and applying AIM Stock analysis, traders can create a robust methodology for identifying AIM entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (143.38) | (136.21) | |
| Operating Profit Margin | (162.49) | (154.37) | |
| Net Loss | (143.38) | (136.21) | |
| Gross Profit Margin | 0.79 | 0.83 |
Current AIM Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AIM analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AIM analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 3.83 | Strong Buy | 2 | Odds |
Most AIM analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand AIM stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of AIM ImmunoTech, talking to its executives and customers, or listening to AIM conference calls.
AIM Stock Analysis Indicators
AIM ImmunoTech stock analysis indicators help investors evaluate how AIM ImmunoTech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AIM ImmunoTech shares will generate the highest return on investment. By understating and applying AIM ImmunoTech stock analysis, traders can identify AIM ImmunoTech position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 27.1 M | |
| Common Stock Shares Outstanding | 48.6 M | |
| Total Stockholder Equity | 10.2 M | |
| Property Plant And Equipment Net | 824 K | |
| Cash And Short Term Investments | 13.1 M | |
| Cash | 5.4 M | |
| Accounts Payable | 6.4 M | |
| Net Debt | -4.7 M | |
| 50 Day M A | 0.2488 | |
| Total Current Liabilities | 8.7 M | |
| Other Operating Expenses | 32.1 M | |
| Non Current Assets Total | 4.8 M | |
| Non Currrent Assets Other | 1.7 M | |
| Stock Based Compensation | 243 K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.